Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
9.96
-0.35 (-3.39%)
At close: Jun 8, 2026, 4:00 PM EDT
10.03
+0.07 (0.67%)
After-hours: Jun 8, 2026, 6:06 PM EDT
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 137 employees as of March 31, 2026. The number of employees increased by 35 or 34.31% compared to the same quarter last year.
Employees
137
Change
35
Growth
34.31%
Revenue / Employee
n/a
Profits / Employee
-$1,351,467
Market Cap
869.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 137 | 35 | 34.31% | 137 | 0 |
| Dec 31, 2025 | 131 | 35 | 36.46% | 131 | 0 |
| Sep 30, 2025 | 122 | 34 | 38.64% | 122 | 0 |
| Jun 30, 2025 | 117 | 28 | 31.46% | 116 | 1 |
| Mar 31, 2025 | 102 | 26 | 34.21% | 101 | 1 |
| Dec 31, 2024 | 96 | 22 | 29.73% | 96 | 0 |
| Sep 30, 2024 | 88 | 18 | 25.71% | 87 | 1 |
| Jun 30, 2024 | 89 | 17 | 23.61% | 80 | 9 |
| Mar 31, 2024 | 76 | 13 | 20.63% | 75 | 1 |
| Dec 31, 2023 | 74 | -12 | -13.95% | 74 | 0 |
| Sep 30, 2023 | 70 | -5 | -6.67% | 70 | 0 |
| Jun 30, 2023 | 72 | -3 | -4.00% | 67 | 5 |
| Mar 31, 2023 | 63 | -8 | -11.27% | 62 | 1 |
| Dec 31, 2022 | 86 | 12 | 16.22% | 83 | 3 |
| Sep 30, 2022 | 75 | 14 | 22.95% | 73 | 2 |
| Jun 30, 2022 | 75 | 24 | 47.06% | 72 | 3 |
| Mar 31, 2022 | 71 | 34 | 91.89% | 70 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Xencor | 260 |
| ARS Pharmaceuticals | 159 |
| Alpha Tau Medical | 121 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
| Lexicon Pharmaceuticals | 81 |
| Inventiva | 77 |
OLMA News
- 5 days ago - Olema Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Olema Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 13 days ago - Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 18 days ago - Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - GlobeNewsWire
- 20 days ago - Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 25 days ago - Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology - TheFly
- 26 days ago - Olema Oncology price target lowered to $35 from $38 at Guggenheim - TheFly